Forum Financial Management LP Has $2.17 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Forum Financial Management LP lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,525 shares of the biopharmaceutical company's stock after purchasing an additional 4,867 shares during the period. Forum Financial Management LP's holdings in Gilead Sciences were worth $2,173,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of GILD. XML Financial LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $203,000. Advisory Alpha LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $260,000. Bartlett & CO. Wealth Management LLC boosted its position in Gilead Sciences by 149.1% during the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 8,697 shares of the biopharmaceutical company's stock worth $803,000 after acquiring an additional 5,205 shares during the last quarter. Avior Wealth Management LLC boosted its position in Gilead Sciences by 33.2% during the fourth quarter. Avior Wealth Management LLC now owns 12,551 shares of the biopharmaceutical company's stock worth $1,140,000 after acquiring an additional 3,129 shares during the last quarter. Finally, Veracity Capital LLC boosted its position in Gilead Sciences by 58.2% during the fourth quarter. Veracity Capital LLC now owns 8,733 shares of the biopharmaceutical company's stock worth $807,000 after acquiring an additional 3,213 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 17,929 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. This represents a 9.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,929 shares of company stock worth $5,644,780. Insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Finally, Piper Sandler lifted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Stock Up 2.3%

Gilead Sciences stock traded up $2.53 during midday trading on Thursday, hitting $110.97. 2,505,397 shares of the stock were exchanged, compared to its average volume of 7,702,939. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The firm has a market cap of $138.03 billion, a P/E ratio of 299.99, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a 50 day moving average price of $105.36 and a two-hundred day moving average price of $100.57.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the firm earned ($1.32) EPS. The company's revenue for the quarter was down .3% compared to the same quarter last year. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.85%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.